Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 24

Sort by

Sort Order Select

Journal Articles

A Polish Adult Leukemia Group (PALG) Prospective International Randomized Multicenter Clinical Trial to Compare the Efficacy of Two Standard Induction Therapies (DA-90 vs DAC) in Acute Myeloid Leukemia (AML) Patients ≤ 60 Years Old (PALG-AML1/2016) - Topline Results

Blood (2024) 144 (Supplement 1): 970.

https://doi.org/10.1182/blood-2024-202365

Published: 2024

Journal Articles

Enhancing Diagnostic and Prognostic Strategies in Secondary HLH: Insights from the Weill-Cornell Medicine Experience

Blood (2024) 144 (Supplement 1): 5379.

https://doi.org/10.1182/blood-2024-210134

Published: 2024

Journal Articles

Opening Pandora's Box: Ultra-Deep Duplex Sequencing in Long Survivors with Acute Myeloid Leukemia

Gail J. Roboz, Nuria Mencia-Trinchant, Gabriela Pereira, Ellen K. Ritchie, Justin D. Kaner, Michael Samuel, Michal Bar-Natan, Jonathan Canaani, Sharmaine Griffith-Baker, Pinkal Desai, Monica L Guzman

Blood (2024) 144 (Supplement 1): 1576.

https://doi.org/10.1182/blood-2024-212090

Published: 2024

Journal Articles

Assessing Role of Comorbidities in Treatment Selection for Older Patients with Acute Myeloid Leukemia

Justin Grenet, Neela Easwar, Akriti G. Jain, Madelyn Burkart, Xiaoyue Ma, Paul Christos, Ellen K. Ritchie, Michael Samuel, Justin D. Kaner, Jonathan Canaani, Aaron D. Goldberg, Shira N. Dinner, Kendra L. Sweet, Gail J. Roboz, Pinkal Desai

Blood (2024) 144 (Supplement 1): 2867.

https://doi.org/10.1182/blood-2024-206340

Published: 2024

Journal Articles

How I use Maintenance Therapy in Acute Myeloid Leukemia

Gail J. Roboz, Jonathan Canaani

Blood blood.2024024010.

https://doi.org/10.1182/blood.2024024010

Published: 2024

Journal Articles

Gilteritinib and Venetoclax for Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia - a Real-World Multicenter Retrospective Study

Eitan Kugler, Inbar Cohen, Ron Ram, Jonathan Canaani, Irina Amitai, Liat Shargian, Boaz Nachmias, Baher Krayem, Avraham Frisch, Itay Levi, Luiza Akria, Pia Raanani, Ofir Wolach, Eitan Kugler

Blood (2023) 142 (Supplement 1): 5911.

https://doi.org/10.1182/blood-2023-185488

Published: 2023

Journal Articles

Interim Results from Clevo: A Non-Interventional Cohort Study Investigating the Clonal Evolution of FMS-like Tyrosine Kinase 3 ( FLT3 ) Mutations during Disease Progression in Patients with Acute Myeloid Leukemia

Cristina Papayannidis, Blanca Boluda, Jonathan Canaani, Pascal Turlure, Ann De Becker, Anand Tandra, Dina Elsouda, Arnaud Houweling, Anil Upadhyay, Isabelle Wouters, Paresh Vyas

Blood (2022) 140 (Supplement 1): 11641–11643.

https://doi.org/10.1182/blood-2022-156296

Published: 2022

Journal Articles

Clinical Predictors for Relapse Among Patients with AML Who Responded to Venetoclax-Based Treatment - a Real-World Prospective Analysis from the Revive Study Group

Blood (2022) 140 (Supplement 1): 9002–9004.

https://doi.org/10.1182/blood-2022-162140

Published: 2022

Journal Articles

Utilization of Antifungal Prophylaxis and Treatment for Newly Diagnosed AML Patients Treated with Venetoclax Based Regimens in Routine Clinical Practice - a Prospective Analysis from the Revive Study

Blood (2022) 140 (Supplement 1): 6162–6164.

https://doi.org/10.1182/blood-2022-163020

Published: 2022

Journal Articles

Defining Current Patterns of Blood Product Use during Intensive Induction Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia Patients

Liron Miller, Mor Freed-Freundlich, Tamer Hellou, Avichai Shimoni, Abraham Avigdor, Mudi Misgav, Jonathan Canaani

Blood (2022) 140 (Supplement 1): 5717–5718.

https://doi.org/10.1182/blood-2022-156096

Published: 2022

Journal Articles

The Occurrence of Thrombosis during Intensive Chemotherapy Treatment for Acute Myeloid Leukemia Patients Does Not Impact on Long-Term Survival

Tamer Hellou, Omri Cohen, Abraham Avigdor, Avichai Shimoni, Mudi Misgav, Jonathan Canaani

Blood (2022) 140 (Supplement 1): 3229–3230.

https://doi.org/10.1182/blood-2022-156099

Published: 2022

Journal Articles

Acute Myeloid Leukemia Patients Requiring Two Cycles of Intensive Induction for Attainment of Remission Experience Inferior Survival Compared with Patients Requiring a Single Course of Induction Chemotherapy

Gal Sharvit, Gabriel Heering, Maya Zlotnick, Arnon Nagler, Abraham Avigdor, Avichai Shimoni, Jonathan Canaani

Blood (2021) 138 (Supplement 1): 3390.

https://doi.org/10.1182/blood-2021-145552

Published: 2021

Journal Articles

ELN 2017 Classification Significantly Impacts on the Risk of Early Death in Acute Myeloid Leukemia Patients Receiving Intensive Induction Chemotherapy

Naama Keren Froim, Gabriel Heering, Gal Sharvit, Maya Zlotnick, Arnon Nagler, Avichai Shimoni, Abraham Avigdor, Jonathan Canaani

Blood (2021) 138 (Supplement 1): 3392.

https://doi.org/10.1182/blood-2021-145551

Published: 2021

Journal Articles

Real World Prospective Observational Multicenter Trial of Venetoclax-Based Therapy for Patients with AML Reveals Unique Patterns of Patient Selection and Treatment Utilization - Revive Study

Ofir Wolach, Itai Levi, David Lavie, Jonathan Canaani, Sigal Tavor, Ilana Hellmann, Tamar Tadmor, Tsila Zuckerman, Galia Stemer, Jenia Berelovich, Keren Ofek, Neta Frankel, Moshe Grunspan, Yishai Ofran, Yakir Moshe

Blood (2021) 138 (Supplement 1): 1246.

https://doi.org/10.1182/blood-2021-147245

Published: 2021

Journal Articles

Evaluating Outcomes of Adult Patients with Acute Lymphoblastic Leukemia Treated on the GMALL Protocol

Danielle Fredman, Yulia Volchek, MD, Gabriel Heering, Keren Shichrur, PhD, Ronit Yerushalmi, MD, Noga Shem-Tov, MD, Elena Ribakovsky, MD, Avichai Shimoni, MD, Abraham Avigdor, MD, Arnon Nagler, MD, Jonathan Canaani, MD

Blood (2020) 136 (Supplement 1): 28–29.

https://doi.org/10.1182/blood-2020-134771

Published: 2020

Journal Articles

A Phase II Study of Bisantrene in Patients with Relapsed/Refractory Acute Myeloid Leukemia

Jonathan Canaani, MD, Ivetta Danilesko, MD, Noga Shem-Tov, MD, Maya Zlotnick, MD, Kira Lozinsky, Ohad Benjamini, Ronit Yerushalmi, MD, Meital Nagar, PhD, Chen Dor, PhD, Avichai Shimoni, MD, Abraham Avigdor, MD, Arnon Nagler, MD

Blood (2020) 136 (Supplement 1): 5–6.

https://doi.org/10.1182/blood-2020-135947

Published: 2020

Journal Articles

First Results from a Nationwide Prospective Non-Interventional Study of Venetoclax-Based 1 st Line Therapies in Patients with Acute Myeloid Leukemia (AML) - Revive Study

Ofir Wolach, MD, Itai Levi, MD, Jonathan Canaani, MD, Tamar Tadmor, MD, Sigal Tavor, MD, Ilana Hellmann, MD, Tsila Zuckerman, MD, David Lavie, MD, Galia Stemer, MD, Raanan Cohen, MD, Ran Afik, PhD, Keren Ofek, PhD, Hilla Banayan, BSc MBA, Inna Kan, PhD, Moshe Grunspan, PhD, Yishai Ofran, MD, Yakir Moshe, MD PhD

Blood (2020) 136 (Supplement 1): 27–28.

https://doi.org/10.1182/blood-2020-139923

Published: 2020

Journal Articles

Haploidentical Stem Cell Transplantation Attenuates the Prognostic Impact of FLT3-ITD in Acute Myeloid Leukemia

Jonathan Canaani, MD, Myriam Labopin, MD, Xiao Jun Huang, William Arcese, MD, Fabio Ciceri, MD, Didier Blaise, MD PhD, Giuseppe Irrera, Lucia Lopez Corral, Benedetto Bruno, MD PhD, Stella Santarone, MD, Maria Teresa van Lint, Antonin Vitek, MDPhD, Jordi Esteve, MD PhD, Mohamad Mohty, MD PhD, Arnon Nagler, MD

Blood (2017) 130 (Supplement 1): 4584.

https://doi.org/10.1182/blood.V130.Suppl_1.4584.4584

Published: 2017

Journal Articles

Donor Age Determines Outcome in Acute Leukemia Patients Undergoing Haploidentical Hematopoietic Cell Transplantation

Jonathan Canaani, MD, Bipin N. Savani, MD, Myriam Labopin, MD, Xiao Jun Huang, Fabio Ciceri, MD, William Arcese, MD, Yener Koc, MD, Johanna Tischer, MD, Didier Blaise, Zafer Gulbas, MD, Maria Teresa Van Lint, MD, Benedetto Bruno, Mohamad Mohty, MD PhD, Arnon Nagler, MD

Blood (2017) 130 (Supplement 1): 850.

https://doi.org/10.1182/blood.V130.Suppl_1.850.850

Published: 2017

Journal Articles

Mechanisms of Acquired Resistance to Gilteritinib Therapy in Relapsed and Refractory FLT3 -Mutated Acute Myeloid Leukemia

Christine M. McMahon, MD, Jonathan Canaani, MD, Bryan Rea, MD, Rachel Lynn Sargent, MD, Jennifer J.D. Morrissette, PhD, David B. Lieberman, MS, CGC, Christopher Watt, MD PhD, Gregory W. Schwartz, PhD, Robert B. Faryabi, PhD, Timothy T. Ferng, MD, Neil P. Shah, MD PhD, Catherine C. Smith, MD, Martin Carroll, MD, Alexander E. Perl, MD

Blood (2017) 130 (Supplement 1): 295.

https://doi.org/10.1182/blood.V130.Suppl_1.295.295

Published: 2017

NARROW

A Polish Adult Leukemia Group (PALG) Prospective International Randomized Multicenter Clinical Trial to Compare the Efficacy of Two Standard Induction Therapies (DA-90 vs DAC) in Acute Myeloid Leukemia (AML) Patients ≤ 60 Years Old (PALG-AML1/2016) - Topline Results

Enhancing Diagnostic and Prognostic Strategies in Secondary HLH: Insights from the Weill-Cornell Medicine Experience

Opening Pandora's Box: Ultra-Deep Duplex Sequencing in Long Survivors with Acute Myeloid Leukemia

Assessing Role of Comorbidities in Treatment Selection for Older Patients with Acute Myeloid Leukemia

How I use Maintenance Therapy in Acute Myeloid Leukemia

Gilteritinib and Venetoclax for Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia - a Real-World Multicenter Retrospective Study

Interim Results from Clevo: A Non-Interventional Cohort Study Investigating the Clonal Evolution of FMS-like Tyrosine Kinase 3 ( FLT3 ) Mutations during Disease Progression in Patients with Acute Myeloid Leukemia

Clinical Predictors for Relapse Among Patients with AML Who Responded to Venetoclax-Based Treatment - a Real-World Prospective Analysis from the Revive Study Group

Utilization of Antifungal Prophylaxis and Treatment for Newly Diagnosed AML Patients Treated with Venetoclax Based Regimens in Routine Clinical Practice - a Prospective Analysis from the Revive Study

Defining Current Patterns of Blood Product Use during Intensive Induction Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia Patients

The Occurrence of Thrombosis during Intensive Chemotherapy Treatment for Acute Myeloid Leukemia Patients Does Not Impact on Long-Term Survival

Acute Myeloid Leukemia Patients Requiring Two Cycles of Intensive Induction for Attainment of Remission Experience Inferior Survival Compared with Patients Requiring a Single Course of Induction Chemotherapy

ELN 2017 Classification Significantly Impacts on the Risk of Early Death in Acute Myeloid Leukemia Patients Receiving Intensive Induction Chemotherapy

Real World Prospective Observational Multicenter Trial of Venetoclax-Based Therapy for Patients with AML Reveals Unique Patterns of Patient Selection and Treatment Utilization - Revive Study

Evaluating Outcomes of Adult Patients with Acute Lymphoblastic Leukemia Treated on the GMALL Protocol

A Phase II Study of Bisantrene in Patients with Relapsed/Refractory Acute Myeloid Leukemia

First Results from a Nationwide Prospective Non-Interventional Study of Venetoclax-Based 1 st Line Therapies in Patients with Acute Myeloid Leukemia (AML) - Revive Study

Haploidentical Stem Cell Transplantation Attenuates the Prognostic Impact of FLT3-ITD in Acute Myeloid Leukemia

Donor Age Determines Outcome in Acute Leukemia Patients Undergoing Haploidentical Hematopoietic Cell Transplantation

Mechanisms of Acquired Resistance to Gilteritinib Therapy in Relapsed and Refractory FLT3 -Mutated Acute Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only